Deal of the Week: One of America’s wealthiest families backs transformative healthcare group

In a world subsumed by the coronavirus, biotech and healthcare companies seem completely irrelevant right now. But that hasn’t stopped a big investment by one of America’s wealthiest families in what is proving to be a transformative healthcare company. 

Koch Disruptive Technologies – the venture group owned by Chase Koch, the son of multi-billionaire Charles Koch – has invested in InSightec. The Israel-based healthcare group makes magnetic-resonance-guided ultrasound technology devices for image-guided acoustic surgery. InSightec has developed transformative technology, which makes it possible to perform completely non-invasive surgery on the brain and other parts of the body. 

As InSightec says on its website: “the surgeon is equipped with a workstation, keyboard and mouse – no scalpel in sight”

Koch Disruptive invested $150 million of growth capital in InSightec after backing them in an earlier funding round. 

InSightec has so far raised nearly $500 million in capital – so its valuation is definitely in unicorn territory. 

Koch Disruptive is certainly splashing the case around since it was founded in late 2017. Last month, it led a Series B round worth $30 million in cloud-based security group Automox. Other investments have included Ibotta, an application that pays its users for shopping online or in-store, Desktop Metals, a 3D print metal parts company, and D2iQ, a cloud-based infrastructure group.